Mathias Haag - Concepedia

Author

Mathias Haag

Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology ORCID

Also Known As

Haag, M., Haag, Mathias, M Haag, M. Haag, Mathias Haag

Publications

2.8K

Citations

H-Index

Concepts

All Affiliations

Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology University of Tübingen Heidelberg University University Hospital Heidelberg University Children's Hospital Tübingen

About

Mathias Haag is an author at Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology specializing in medicine, biochemistry, and hepatitis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	15	2.2K
2	Biochemistry	7	7	1K
3	Natural Sciences	5	5	905
4	Engineering	1	1	25
5	Biomedical Engineering	1	1	25

Mathias Haag

Publications

2.6K

Citations

H-Index

Page 1

	Year	Citations
Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study Pavel Bogomolov, A. A. Alexandrov, M. V. Macievich, Journal of Hepatology Chronic Hepatitis DHepatologyViral HepatitisImmunologyFirst Results	2016	380
The genetic interactome of prohibitins: coordinated control of cardiolipin and phosphatidylethanolamine by conserved regulators in mitochondria Christof Osman, Mathias Haag, Christoph Potting, The Journal of Cell Biology GeneticsMolecular BiologyCytoskeletonCellular PhysiologyMitochondrial Biogenesis	2009	293
Intramitochondrial Transport of Phosphatidic Acid in Yeast by a Lipid Transfer Protein Melanie Connerth, Takashi Tatsuta, Mathias Haag, Science Proteinlipid InteractionPhosphatidic AcidMolecular BiologyCytoskeletonLipid Movement	2012	229
TRIAP1/PRELI Complexes Prevent Apoptosis by Mediating Intramitochondrial Transport of Phosphatidic Acid Christoph Potting, Takashi Tatsuta, Tim König, Cell Metabolism Intramitochondrial TransportSignal TransductionMitochondrial FunctionBiochemistryPhosphatidic Acid	2013	219
First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B Antje Blank, Christoph Markert, Nicolas Hohmann, Journal of Hepatology Novel Hepatitis BFirst-in-human ApplicationViral HepatitisMedicineImmunology	2016	214
DNAJC19, a Mitochondrial Cochaperone Associated with Cardiomyopathy, Forms a Complex with Prohibitins to Regulate Cardiolipin Remodeling Ricarda Richter‐Dennerlein, Anne Korwitz, Mathias Haag, Cell Metabolism Cardiolipin RemodelingCardiomyopathyMolecular PhysiologyMitochondrial BiogenesisMitochondrial Function	2014	200
A mitochondrial phosphatase required for cardiolipin biosynthesis: the PGP phosphatase Gep4 Christof Osman, Mathias Haag, Felix Wieland, The EMBO Journal BiosynthesisLipid SynthesisBiochemistryMitochondrial FunctionLipid Metabolism	2010	138
Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial Heiner Wedemeyer, Katrin Schöneweis, Pavel Bogomolov, The Lancet Infectious Diseases HepatologyViral HepatitisPharmacologyHepatitis BHepatitis	2022	138
Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-infection Heiner Wedemeyer, Pavel Bogomolov, Antje Blank, Journal of Hepatology Viral PersistenceViral HepatitisAntiviral TherapyHepatitisMyrcludex B	2018	121
Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy Anna Reustle, Moreno Di Marco, Carolin Meyerhoff, Genome Medicine	2020	101

Page 1